Academy’s Monthly Bulletin: May 2024

Academy's Monthly Bulletin: May 2024

A Monthly Newsletter Dedicated to Our Academy Membership Community!

Academy's Update for May 2024:

Here is the summary of our posted Lectures, YouTube videos & Updates for May 2024:

(1) Managing Clozapine's Adverse Events

In the following lecture series by Psychiatry Education Forum Academy, Dr. Harvinder Singh will discuss the hematologic, cardiac, neurological, and gastro-intestinal adverse events with clozapine.


  1. To learn the types of clozapine’s adverse events.
  2. Relationship of these adverse events with clozapine’s dose and duration of treatment.
  3. Evaluation and Management of clozapine’s adverse events.
  4. Discuss monitoring protocols with clozapine’s hematologic and cardiac adverse events.
  5. Learning when to re-challenge vs not re-challenge with clozapine?

(2) Antipsychotics Induced Akathisia: Treatment Options

Akathisia, a distressing side effect of antipsychotic medications, can significantly impact an individual’s quality of life. Characterized by an intense inner restlessness and the inability to sit still, it’s crucial to address this condition effectively to enhance patient well-being.

We posted this new academy content, where Dr. Harvinder Singh has discussed this clinically relevant topic of Antipsychotics Induced Akathisia into following sections:

  1. What is Akathisia?
  2. Which Antipsychotics are Low Risk for Akathisia?
  3. Primary Clinical Recommendations for Antipsychotics Induced Akathisia.
  4. Top 6 Recommended Adjunctive Medications for Antipsychotics Induced Akathisia?
  5. Based on most recent publications: which Adjunctive Medication(s) are not recommended for Antipsychotics Induced Akathisia?

(3) Xanomeline-Trospium Chloride (KarXT) for Schizophrenia

on May 1, 2024, JAMA Psychiatry published the positive results of EMERGENT-3 trials for this potential non-dopaminergic medication for schizophrenia. 

KarXT is a combination of two drugs: xanomeline and trospium chloride. This innovative therapy represents a significant departure from traditional antipsychotic treatments.

Watch our YouTube video on the likely mechanism of action for KarXT. This blog post will also summarize the following:

  1. Mechanism of Action: how is this different from other antipsychotics?
  2. Dosing: How to Dose & Titrate?

(4) Clinical Case Discussion: Antidepressants & Hyponatremia Risk

Dr. Satinderpal Kaur (Family Medicine) & Dr. Harvinder Singh (Psychiatry) will continue their discussion to integrate clinical cases from Psychiatry and Medicine.
Our 7th clinical case discussion will focus on:
(1) Hyponatremia: Definition & Severity
(2) Symptoms of Hyponatremia: Mild & Severe
(3) Initial Assessment of Hyponatremia
(4) Understanding Laboratory Evaluation of Hyponatremia
(5) Understanding SIADH.
(6) Important Differential Diagnosis.
(7) Medications as cause for SIADH.
(8 Antidepressants & Hyponatremia: Likely Mechanism.
(9) Antidepressants & Hyponatremia: Risk Factors
(10) Antidepressants & Hyponatremia: High Risk Medications.
(11) Antidepressants & Hyponatremia: Moderate Risk Medications.
(12) Antidepressants & Hyponatremia: Lowest Risk Medications.
(13) Clinical Case Discussion

(5) Facebook Live 003: New Treatments in Pipeline

Facebook LIVE is a new feature for our academy students. Join us for our 3rd Facebook Live session with Dr. Harvinder Singh.

This session is dedicated to the discussion of the following three potential medications in the pipeline:

(1) Xanomeline-Trospium Chloride (KarXT) for Schizophrenia:

  • Mechanism of Action How to Dose?
  • EMERGENT-3 trial results
  • Common Side Effects

(2) Subcutaneous Olanzapine Extended-Release Injection (TEV-‘749):

  • Efficacy results from Phase 3 SOLARIS trial.
  • Does this medication have Post-Injection Delirium/Sedation Syndrome?

(3) Liafensine for Treatment-Resistant Depression:

  • Mechanism of Action.
  • Results from Biomarker Guided Phase 2b Clinical Trial (ENLIGHTEN)



This is a closed membership for medical professionals only.

  • 400+ Clinically Relevant Chapters: Each chapter within these sections is of direct clinical relevance for your daily practice. (Table of Content)
  • Journal Club: we will post the most recently published psychiatry articles relevant to your daily clinical practice. (Read Content)
  • Clinical Case Discussion: Dr. Singh (Psychiatry) and Dr. Kaur (Family Medicine) discuss clinical cases to integrate the clinical cases from Psychiatry and Medicine. (Read Content)
  • Discussion Forum & Community: Connect with other medical professionals and discuss your difficult-to-treat clinical cases. (Academy Network)
  • Goal: is to have all important clinically relevant topics in one place for ease of access.
$ 150/YR
$ 99/YR


Email us your student information (program information and way to confirm your student status) to:

© 2024 All Rights Reserved.

Join Email Newsletter

* indicates required

Related Articles


Your email address will not be published. Required fields are marked *